0.9% sodium chloride clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis
This study is looking into a new medicine, LY3541860, for people with relapsing multiple sclerosis (RMS). Researchers want to see if it can reduce the number of new spots on the brain (lesions) compared to a dummy treatment (placebo).
For: Relapsing Multiple SclerosisItaly · Lithuania · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60 Years And Older with a History of Urinary Tract Infection in the Past 2 Years
This study is testing a new vaccine to prevent serious infections caused by certain types of E. coli bacteria in adults aged 60 and over who have had urinary tract infections. It compares the vaccine to a dummy treatment.
For: Invasive Extraintestinal Pathogenic Escherichia coli DiseaseNetherlands · Czechia · Germany - AuthorisedPhase II and Phase III (Integrated)
A Randomised, Observer-Blind Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of a Group B Streptococcus Vaccine (GBS-NN/NN-2) when 1 Dose is Administered Concomitantly with the TDaP Vaccine in Healthy Non-pregnant Women 18 to 49 years of age Compared to when Each Vaccine is Administered Alone
This study is looking at a new vaccine to prevent Group B Strep infection in women aged 18 to 49. It checks how well the vaccine works and if it's safe when given with a routine tetanus, diphtheria, and whooping cough jab, or if given alone.
For: Prevention of Group B streptococcus infectionBelgium · Poland - AuthorisedTherapeutic exploratory (Phase II)
J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
This study is looking into a new medicine called LY3537021 (also known as Lagipra) to help prevent sickness and vomiting caused by chemotherapy. It compares the new medicine to a dummy pill (placebo) and other common anti-sickness treatments in adults having cancer treatment.
For: Drug-Related Side Effects and Adverse Reactions · Nausea · NeoplasmsRomania · Spain · France